MindImmune Therapeutics Appoints Brad Margus and Robert Michael Poole, MD FACP, to its Board of Directors
Industry leaders bring deep background and experience, with Mr. Margus assuming role as Board Chair
South Kingstown, RI – January 3, 2024
MindImmune Therapeutics, a pre-clinical stage biopharmaceutical company focused on neuroinflammation targeting Alzheimer’s disease as lead indication, today announced the appointments of Brad Margus and Robert Michael Poole, MD, FACP to its Board of Directors, with Mr. Margus assuming the role of Board Chair.
Mr. Margus is currently co-founder and Board Chair of Cerevance, having served as CEO since the company’s inception in 2016. Previously he served as co-founder and CEO at Envoy Therapeutics from 2009 to 2013. Before that, he served as co-founder and CEO and later Vice Chairman of Perlegen Sciences from 2000 to 2008. Mr. Margus received his MBA from Harvard Business School in 1986.
Dr. Poole is a co-founder and advisor to Neumora, a company pioneering a fundamentally new approach to the way treatments for brain diseases are developed. He also serves as advisor to Gates Ventures, having been previously affiliated with the Bill and Melinda Gates Foundation in several capacities. He has served in executive roles in neuroscience drug development with Parke Davis, Pfizer, Wyeth and at AstraZeneca. Dr. Poole earned his undergraduate degree at the University of California, Berkeley, and his medical degree from the UC San Diego School of Medicine.
“We are delighted to welcome Brad and Mike to MindImmune’s Board, and we look forward to working with both as we advance our lead program into clinical development,” said Stevin Zorn, PhD, co-founder and CEO of MindImmune. “The leadership that Brad will bring as Board Chair, given his deep experience in launching and financing several prominent biotech companies, comes at a critical time in MindImmune’s corporate development. Further, the background and expertise that Mike brings to bear in terms of CNS-focused drug discovery and development will prove invaluable as we move toward clinical
Mr. Margus stated, “I am pleased to join as Chair at MindImmune at this critical juncture as the company raises capital from select investors and advances its lead program into clinical development. The company’s novel approach has the potential to become a fundamentally new therapeutic strategy for treating neuro-degenerative disease.”
Dr. Poole stated, “I am thrilled to reunite with former colleagues in the ground-breaking approach beingpursued at MindImmune. They are taking a fundamentally new direction to help solve some of the most challenging therapeutic problems in medicine.”
About MindImmune Therapeutics
MindImmune Therapeutics is a preclinical-stage, venture-backed company focused on neuroinflammation as means of addressing neurodegenerative disease. The company’s lead program seeks to inhibit immune cell recruitment from the periphery in response to pathology in patients with Alzheimer’s disease. If successful in clinical development, it is an approach which would represent a fundamental breakthrough for the field. Launched in collaboration with the Ryan Institute for Neuroscience Research at the University of Rhode Island, the company is advancing an antibody-based therapeutic in late-stage preclinical development. The company’s investors include Pfizer Ventures, Dolby Family Ventures, the Alzheimer’s Drug Discovery Foundation (ADDF), Trend Venture, RightHill Ventures (an affiliate of the Slater Technology Fund), and several other investors.